Continued research and support that connects to
patients’ lives

CSL Behring’s commitment to product innovation

CSL Behring draws on a heritage of innovation that includes producing the world’s first pasteurized plasma protein solution and marketing the world’s first high-activity recombinant factor VIII (rFVIII) therapy for hemophilia A patients using sucrose rather than albumin for stabilization.1

In addition to developing Helixate FS for hemophilia A, CSL Behring has advanced treatment for a variety of other bleeding disorders, including von Willebrand disease (VWD) and congenital fibrinogen deficiency. Today, CSL Behring continues to pioneer new coagulation biotherapies and technologies.

Our progressive portfolio: Developing more products for serious factor deficiencies

CSL Behring is continually expanding its product offerings to increase treatment options for patients with serious and rare factor deficiencies. Products in development include:

  • Balanced prothrombin complex concentrate (PCC)
  • Factor XIII replacement therapy

The newest frontier in innovation: Extended half-life technology

Based upon its commitment to producing innovations that are true improvements in medical therapy and patient care, CSL Behring is currently developing proprietary technology to extend the half-life of our recombinant factor concentrates.

  • CSL Behring is currently researching the potential of albumin fusion technology to prolong half-life by linking albumin to coagulation factor compounds2
  • Although research is ongoing, early results so far are very promising3

Education and Advocacy

CSL Behring works closely with patient groups, including hemophilia patients, on a range of issues that affect them, providing everything from education to advocacy. We also work with legislators and regulators around the world to help ensure that patients can get access to safe, high-quality plasma-derived and recombinant products that are affordable and/or appropriately reimbursed.

The Local Empowerment for Advocacy Development (LEAD) Program is a novel program through which CSL Behring partners with local patient organizations on the state level. CSL Behring believes that successful advocacy results from the empowerment of those that are impacted by a particular issue.

We recognize that many local patient advocacy organizations need to expand their advocacy capabilities in order to address both present and future needs. CSL Behring’s LEAD Program assists local advocacy organizations in the development of their advocacy capabilities.

  • Grants are available to groups who:
    • Need support for an existing advocacy initiative or are planning a new initiative
    • Are building a database of those who are interested in advocacy
  • LEAD also supports Raise Your Voice!, an advocacy training program for young organizers (ages 16-23). CSL Behring will collaborate with partnering state advocacy organizations to develop advocacy training programs, to offer legislative visits and to provide interesting political speakers.

Click here to learn more about the LEAD program or Raise Your Voice!.

Supporting the initiatives of the bleeding disorders community

Since 2003-2004, CSL Behring has awarded more than $6 million to support basic science and clinical research in the area of bleeding disorders.4 CSL Behring also supports a variety of charitable, scientific, and educational causes, including:

  • Support for “Campaign for our Future” of the National Hemophilia Foundation and the Voices Campaign of the Hemophilia Federation of America
  • Project SHARE, which provides financial assistance and factor products to help support the bleeding disorders community in developing countries*
  • Continued financial support for key research areas through grants to hemophilia treatment centers and other nonprofit organizations
  • Global research grants through the Professor Heimburger award, dedicated to supporting preclinical and clinical research in coagulation
  • Funding for Patient Services Incorporated (PSI) (https://www.patientservices.org), a nonprofit organization that helps patients living with chronic illnesses pay for therapy

* Project SHARE is operated by LA Kelley Communications, Inc.

References:

1. Freudenberg W, inventor; Behringwerke Aktiengesellschaft, assignee. Stabilized factor VIII preparations. US Patent 5,565,427. October 15, 1996.

2. Schulte S. Half-life extension through albumin fusion technologies. Thromb Res. 2009;124(suppl 2):S6-S8.

3. Data on file. CSL Behring LLC.

4. CSL Limited: Our Corporate Responsibility. Available at: www.cslbehring.com/docs/350/505/CSL-Corporate-Responsibility-Report-2009.pdf Accessed May 21, 2010.

Next: Request More Information »

Important Safety Information

Helixate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Helixate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to antihemophilic factor. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Helixate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

Please see the full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.